An update from Panbela Therapeutics (PBLA) is now available.
Panbela Therapeutics, Inc. has announced an update on the expected timeline for the interim data analysis of its ASPIRE trial. The update, which was released on April 22, 2024, is intended to inform stakeholders about the progress of the trial. However, this information is not considered officially filed with the SEC and does not carry the associated liabilities, nor is it included in any regulatory filings unless specifically referenced.
For a thorough assessment of PBLA stock, go to TipRanks’ Stock Analysis page.
